Lung Cancer

J. Russell Davis, MD, clinical professor, University of Missouri-Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, discusses the benefits of robotics in thoracic surgery.

Kwok-Kin Wong, MD, PhD, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine, and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discusses the current landscape of non–small cell lung cancer (NSCLC).

Kwok-Kin Wong, MD, PhD, discusses updates in non–small cell lung cancer and the importance of enrolling patients in clinical trials to further progress the field.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in non–small cell lung cancer.

Elaine Shum, MD, discusses the rapidly evolving treatment options for patients with oncogene-driven non–small cell lung cancer.

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses recent advances in immunotherapy for the treatment of patients with small cell lung cancer.

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.

Alexander E. Drilon, MD, discusses the emerging targetable biomarkers in non–small cell lung cancer and the investigational therapies designed to target them.

Patrick M. Forde, MBBCh, discusses the future of immunotherapy in early-stage non–small cell lung cancer.

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

Chul Kim, MD, MPH, discusses the additions of EGFR inhibitors to the lung cancer armamentarium and how to best select therapy for these patients.

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

Michael D. Mix, MD, disucsses the use and optimization of SBRT in the management of patients with early-stage non–small cell lung cancer and oligometastatic disease.

Robert J. Cerfolio, MD, discusses how the use of surgery has significantly evolved over the years and how advances made in robotic surgery improve quality of life of those who need to undergo these procedures.

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Amishi Desai, MD, assistant professor of medicine at Upstate University Hospital, discusses the use of immunotherapy in patients with non–small cell lung cancer (NSCLC) with PD-L1 expression less than 1%.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.

Some immune-related adverse events associated with immune checkpoint inhibitor therapies may prove to be higher than the data reported in the trials that led to the drugs’ initial FDA approval.

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Manju P. Paul, MD, assistant professor of medicine at Upstate University Hospital, discusses the pulmonologist’s role as part of the multidisciplinary approach in treating patients with non–small cell lung cancer (NSCLC).